To ask the Secretary of State for Health and Social Care, whether the joint accelerated approvals pathway operated by the National Institute for Health and Care Excellence and Medicines and Healthcare products Regulatory Agency will enable tumour-agnostic licensing and other NHS access routes to ensure that patients with rare cancers can receive genomically-matched treatments on the NHS.
The Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) are working to deliver the Government’s ambitions, as set out in the 10-Year Health Plan for England and the Life Sciences Sect...
Rare Cancers: Medical Treatments